LAKE FOREST, Calif.,
March 11, 2015 /PRNewswire/ --
Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of
advanced cryogenic logistics solutions for the life sciences
industry, serving markets including immunotherapies, stem cells,
cell lines, clinical research organizations, vaccine manufacturers
and reproductive medicine, today announced that it is co-sponsoring
the Alliance for Regenerative Medicine 3rd Annual REGENMED Investor
Day, to be held March 25, 2015 at the
Metropolitan Club in New York
City.
The one-day, high impact program provides institutional,
strategic and venture investors with unique insight into
regenerative medicine and advanced therapy-based treatments and
tools. Clinical and commercial experts will be on-hand to address
specific questions regarding the outlook for these products, as
well as offer insight into how advanced therapies could impact the
standard of care in key therapeutic areas such as cardiovascular
disease, wound healing and tissue repair, ophthalmology,
neurodegenerative diseases, diabetes and oncology. The event will
also feature discussions with key opinion leaders in the industry,
life science investment experts and analysts covering the sector as
well as presentations by more than 30 leading companies from across
the globe.
"We are excited to be an industry sponsor to this annual event
organized by the Alliance for Regenerative Medicine," stated
Jerrell Shelton, Chief Executive
Officer of Cryoport. "The participating and presenting companies
play a vital role in the advancement of many new and potentially
life-saving cell-based therapies. Cryoport offers validated and
best-in-class cryogenic logistics solutions to support these
important new developments in regenerative medicine. For
example, we can support their logistics needs from early clinical
trial distribution to commercialization strategies for allogeneic
and autologous cell-based immunotherapies."
According to a 2015 State of the Industry Briefing for
regenerative medicine and advanced therapies given by ARM, there
are 375 clinical trials in various stages of development and over
60 approved products in the space. A recent industry report states
that the global market for regenerative medicine is expected to
grow at a compound annual growth rate of 20% from 2014 to 2019.
Cryoport is well positioned to become the logistics partner of
choice in this growing market.
About Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine's (ARM) mission is to
advance regenerative medicine by representing, supporting and
engaging all stakeholders in the field, including companies,
academic research institutions, patient advocacy groups,
foundations, health insurers, financial institutions and other
organizations.
Based in Washington, DC, ARM is
a global advocacy organization that promotes legislative,
regulatory, reimbursement, investment, technical and other
initiatives to accelerate the development of safe and effective
regenerative medicine technologies. ARM also works to increase
public understanding of the field and its potential to transform
human healthcare. For more information please visit
www.alliancerm.org.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. We provide leading edge logistics
solutions for biologic materials such as immunotherapies, stem
cells, CAR-T cells, and reproductive cells for clients worldwide
including points-of-care, CRO's, central laboratories,
pharmaceutical companies, contract manufacturers, and university
researchers. Our packaging is built around our proprietary Cryoport
Express® liquid nitrogen dry vapor shippers, which are
validated to maintain a constant -150°C temperature for a 10 day
dynamic shipment duration. Our information technology centers
around our Cryoportal™ Logistics Management Platform, which
facilitates management of the entire shipment process. Cryoport is
the preferred cryogenic logistics solutions partner to the world's
largest shipping companies controlling more than 85% of the world's
air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2014. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
Logo- http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-co-sponsors-the-alliance-for-regenerative-medicine-3rd-annual-regenmed-investor-day-300048679.html
SOURCE Cryoport, Inc.